BIOTRONIK’s Selectra still left ventricular lead delivery program receives European market approval BIOTRONIK, a leading producer of implantable cardiac pioneer and devices of wi-fi remote monitoring technologies, announced the European market place authorization of the Selectra still left ventricular lead delivery program today. ‘BIOTRONIK spent time and effort understanding electrophysiologists’ desires and examining the problems they encounter with current business lead delivery systems. It really is this intensive insight which has formed the foundation for engineering Selectra’s advanced style,’ commented Marlou Janssen, Vice President of Global Advertising & Product sales metformin-hydrochloride.net http://metformin-hydrochloride.net .
Today announced that it offers entered right into a research collaboration with Merck, through a subsidiary, for the advancement and validation of a novel biomarker with potential program in the administration of lipid disorders. BG Medicine will pursue advancement and validation of an immunoassay and investigate its scientific utility as a biomarker. If effective, BG Medication plans to full the development and validation research and look for regulatory clearance for the check. BG Medication is qualified to receive certain payments upon accomplishment of established milestones. Source BG Medicine.. BG Medication, Merck collaborate in advancement of novel biomarker for lipid disorder management BG Medicine, Inc.